| Ytd | -10.05% | |
| 1y | 37.61% |
| Open | 31.88 | Prev Close | 32.34 | Low | 31.61 | High | 32.63 | Mkt Cap | 3.78B |
| Vol | 30.80K | Avg Vol | 1.31M | EPS | -1.59 | P/E | -20.34 | Forward P/E | -27.71 |
| Beta | 0.08 | Short Ratio | 6.98 | Inst. Own | 106.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 33.51 | 200-d Avg | 34.01 | 1yr Est | 49.84 |
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
US stocks, including Monster Beverage Corp, rose on Friday. Monster Beverage reported better-than-ex
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo